Business
Lifeward Announces New ReWalk® Data Presented at ASIA 2026 Conference Demonstrating a Comprehensive Longitudinal Safety Analysis for a Powered Exoskeleton
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six years Zero fractures reported across 97 German users since 2018, spanning broad patient profiles and bone health conditionsFindings reinforce safety profile and support expanded adoption of ReWalk for spinal cord injury mobility Lifeward CEO Mark Grant addressed the 53rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people
About this update from Lifeward Ltd.
Global data since 2013 show just 3% lifetime fracture prevalence, declining to 0.3% over the past six years Zero fractures reported across 97 German users since 2018, spanning broad patient profiles and bone health conditionsFindings reinforce safety profile and support expanded adoption of ReWalk for spinal cord injury mobility Lifeward CEO Mark Grant addressed the 53rd ASIA Annual Scientific Meeting audience with a speech regarding Lifeward and its vision for restoring full function to people living with spinal cord injuries HUDSON, Mass., and YOKNEAM ILLIT, Israel, May 04, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced the presentation of new clinical data on the ReWalk® Personal Exoskeleton at the American Spinal Injury Association (ASIA) 2026 Annual Scientific Meeting, which took place in San Antonio, Texas on April 24 – 26, 2026. The poster presentation titled “Prevalence, Location, and Other Data Regarding Lower Extremity Fractures during Clinical Application of the ReWalk Exoskeleton 2013-2025” highlights over a decade of real-world data evaluating the prevalence and characteristics of lower extremity fractures associated with ReWalk use. The results demonstrate a consistently favorable and improving safety profile, reinforcing confidence in the device among clinicians, patients and caregivers. While exoskeletons have been in use for mobility and increased activity in spinal cord injury for over a decade, evaluations of risk with their clinical application have been limited relatively rare. Lifeward’s clinical study and findings represent a comprehensive longitudinal safety analysis of powered exoskeleton use in spinal cord injury to date. The near elimination of fractures in recent years, particularly in a real-world national cohort, supports the growing clinical consensus that exoskeleton-assisted walking can be both effective and safe when properly implemented. “These new data are an important milestone for Lifeward and our ReWalk powered exoskeleton, as well as for the broader field of exoskeleton-assisted mobility,” said Mark Grant, Lifeward’s Chief Executive Officer. “We are seeing low rates of adverse events globally and a clear and sustained improvement ...